Skip to main content
Signal8

Telo Genomics Corp. (TDSGF)

Sector: Medical - Diagnostics & Research

Industry: Medical - Diagnostics & Research

Telo Genomics Corp. logo

Telo Genomics Corp.

OTC:TDSGFHealthcare
CLOSED
Mkt Cap$3.01M
EV-
Float97.41M
O/S100.43M
VOL200 sh
$ Vol$6
RVOL0.04×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Telo Genomics Corp. logoOTC:TDSGFClosed
Historical Data
DateOpenHighLowCloseVolume
Nov 10, 20260.02960.02960.02960.0296200
Nov 9, 20260.02950.02950.02950.0295800
Nov 5, 20260.04020.04020.04020.04022,200
Oct 30, 20260.03600.03600.03600.036010,000
Oct 29, 20260.03600.03600.03600.036010,000
Oct 16, 20260.05110.05110.04420.044211,200
Oct 15, 20260.04740.04740.04740.04746,000
Oct 13, 20260.05670.05670.05670.056723,000
Oct 12, 20260.02760.05530.02760.049165,000
Oct 9, 20260.03740.04980.03740.0498182,500
Oct 8, 20260.04370.05000.04370.050040,040
Oct 7, 20260.04100.05620.03090.0351107,700
Oct 6, 20260.04240.04240.04240.04241,000
Oct 5, 20260.03710.03710.03710.037120,000
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

Telo Genomics Corp. is a biotechnology enterprise focused on developing and commercializing sophisticated predictive technologies. Their mission is to enable personalized treatment approaches for patients facing specific health challenges.

The company's central offering is a telomere analysis platform, which provides both diagnostic insights and prognostic assessments. This platform leverages liquid biopsies and related innovations, with a particular emphasis on applications within oncology (cancer) and neurological diseases. A flagship product, Telo-MM, is a solution designed to equip healthcare professionals with crucial, actionable information for managing Multiple Myeloma, a type of blood cancer.

Additionally, the company provides TeloView, a proprietary software platform used to precisely measure specific telomere features unique to each patient. Telo Genomics serves a diverse client base, including pathologists, clinicians, academic researchers, and drug developers. They have a collaborative agreement with the Mayo Clinic to conduct validation studies for their Telo-MM tests concerning multiple myeloma. Founded in 2014, the company was initially known as 3D Signatures Inc. before officially changing its name to Telo Genomics Corp. in April 2019.

Its headquarters are located in Toronto, Canada.

Key Metrics
Market Cap$3.01M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 100.43M shares outstanding

SectorHealthcare
IndustryMedical - Diagnostics & Research
ExchangeOTC
CountryCACA
IPO Date-
Shares Outstanding100.43M
Authorized Shares
Float97.41M
52-Week Range
Volume
Average Daily Volume4.64K

30d Avg

4.64K

60d Avg

28.83K

90d Avg

29.33K

Earnings
Dividend History
No dividend history available